A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Sponsor
The First Affiliated Hospital of Soochow University
Study ID
NCT06497452
Status
Recruiting
Apply to this trial

Conditions

  • B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Glofitamab — DRUG
    Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling

Study Details

The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.

Key Dates

Start date
Jun 1, 2024
Status verified
Jun 2024
Primary completion
Dec 31, 2025
Completion
Jun 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Observational Cohort

Primary Outcome Measure

Best Complete Response Rate (bCRR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma [ Time Frame: Baseline up to EOT (approximately 9 months) ]

Central Contacts

Related Studies